|
|
Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) |
|
*Market share is calculated based on total revenue.
News about Quoin Pharmaceuticals Ltd Contracts |
November 5, 2024
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a noteworthy player in the realm of clinical-stage specialty pharmaceuticals, has made significant strides in its commitment to developing cutting-edge treatments for rare and orphan diseases. As announced from their headquarters in Ashburn, Virginia on November 5, 2024, the company has commenced clinical testing of its lead product, QRX003, in a young child diagnosed with Netherton Syndrome (NS) a rare genetic condition characterized by a triad of symptoms, including congenital ichthyosis, atopic diathesis, and hair abnormalities. Currently, there are no approved treatments or cures available for this debilitating disease.In a landmark development for Quoin Pharmac...
|
June 25, 2024
ASHBURN, Va., June 25, 2024 In a significant move underscoring its commitment to the rare disease community, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, announces its role as a Bronze Sponsor for the Foundation for Ichthyosis and Related Skin Types (FIRST) 2024 national conference. The event will take place in Albuquerque, New Mexico from June 28-30, 2024.The FIRST national conference represents a critical convergence point for patients, families, researchers, and healthcare professionals dedicated to understanding and managing ichthyosis and related skin types. As a debilitating genetic disorder...
|
June 12, 2024
Quoin Pharmaceuticals recently announced the signing of a significant research agreement with University College Cork (UCC) in Ireland. This exciting collaboration aims to focus on the development of unique topical rapamycin (sirolimus) formulations as potential treatments for a range of rare and orphan diseases. Rapamycin, a potent immunosuppressive drug originally derived from bacteria found on Easter Island, has already demonstrated its efficacy in various medical applications. However, its utilization as a topical treatment for rare diseases remains largely unexplored. This research agreement between Quoin Pharmaceuticals and UCC seeks to bridge this gap and uncover new possibilities in saving lives and ...
|
March 4, 2024
FDA Grants Quoin Pharmaceuticals Clearance to Include Teen Patients in Ongoing Netherton Syndrome Clinical Trials: Potentially Expediting Recruitment and Enhancing Data AnalysisIn a significant development, Quoin Pharmaceuticals has received FDA clearance to enroll teenage patients in their ongoing clinical studies for the treatment of Netherton Syndrome. This regulatory approval is expected to expand the pool of eligible participants, potentially accelerating the recruitment process and leading to a more comprehensive and robust dataset.Netherton Syndrome is a rare and debilitating genetic skin disorder that primarily affects infants and young children. Characterized by severe skin inflammation, impaired sk...
|
Publicly Traded Peers of Quoin Pharmaceuticals Ltd
Athersys Inc
Share Performance
-96.93%
This Quarter
|
Athersys Inc
Profile
Athersys Inc's business model revolves around the development and commercialization of novel cellular therapeutics.
More about Athersys Inc's Market Share
|
Reviva Pharmaceuticals Holdings Inc
Share Performance
-60.15%
This Quarter
|
Reviva Pharmaceuticals Holdings Inc
Profile
Reviva Pharmaceuticals Holdings Inc follows a research and development (R&D) business model focused on discovering and developing novel therapeutics for various diseases. The company leverages its expertise in drug discovery and innovative technologies to identify potential drug candidates and advance them through preclinical and clinical stages. By collaborating with partners or licensing its products, Reviva aims to bring its discoveries to the market and address unmet medical needs.
More about Reviva Pharmaceuticals Holdings Inc 's Market Share
|
Sunshine Biopharma Inc
Share Performance
-20.08%
Over The Past 5 Days
|
Sunshine Biopharma Inc
Profile
Sunshine Biopharma Inc is a pharmaceutical company that focuses on developing and commercializing drugs for the treatment of cancer and other diseases. They utilize their expertise in drug discovery and development to create innovative treatments that target specific molecular targets in order to deliver more effective and personalized therapies for patients.
More about Sunshine Biopharma Inc 's Market Share
|
Ayala Pharmaceuticals Inc
Share Performance
0.00%
This Quarter
|
Ayala Pharmaceuticals Inc
Profile
Ayala Pharmaceuticals Inc is a biopharmaceutical company focused on developing targeted therapies for patients with rare and aggressive cancers. Their business model revolves around leveraging scientific expertise and strategic partnerships to advance their pipeline of potential treatments and ultimately bring them to market.
More about Ayala Pharmaceuticals Inc 's Market Share
|
Longeveron Inc
Share Performance
-64.35%
One Year
|
Longeveron Inc
Profile
Longeveron Inc's business model involves the development and commercialization of regenerative medicine products using mesenchymal stem cells for various medical conditions.
More about Longeveron Inc 's Market Share
|
Oncotelic Therapeutics Inc
Share Performance
+48.04%
30 Days
|
Oncotelic Therapeutics Inc
Profile
Oncotelic Therapeutics Inc is a biotechnology company that focuses on developing and commercializing novel therapeutics for the treatment of cancer. Their business model revolves around conducting research to develop innovative drugs and therapies, and subsequently bringing those products to market to generate revenue and improve patient outcomes in cancer treatment.
More about Oncotelic Therapeutics Inc 's Market Share
|
Renovaro Inc
Share Performance
+4.11%
This Year
|
Renovaro Inc
Profile
Renovaro Biosciences Inc is a biotechnology company that focuses on developing innovative therapies and technologies for regenerative medicine. Their business model involves conducting research and development, and partnering with pharmaceutical companies to bring their products to the market.
More about Renovaro Inc 's Market Share
|
Ovid Therapeutics Inc
Share Performance
-54.17%
This Year
|
Ovid Therapeutics Inc
Profile
Ovid Therapeutics Inc's business model is focused on developing and commercializing innovative medicines for the treatment of rare neurological disorders.
More about Ovid Therapeutics Inc 's Market Share
|
Capricor Therapeutics inc
Share Performance
-0.16%
Over The Past 5 Days
|
Capricor Therapeutics inc
Profile
Capricor Therapeutics Inc's business model revolves around developing innovative regenerative medicine therapies for the treatment of diseases that have unmet medical needs.
More about Capricor Therapeutics inc 's Market Share
|
Regen Biopharma Inc
Share Performance
-8.32%
This Year
|
Regen Biopharma Inc
Profile
Regen Biopharma Inc is a biotechnology company that focuses on developing innovative treatments for diseases like cancer and autoimmune disorders. Their business model revolves around conducting research and development activities to create novel therapeutics and licensing or partnering with larger pharmaceutical companies for further development and commercialization. By leveraging their scientific expertise and strategic collaborations, Regen Biopharma aims to bring cutting-edge medical solutions to the market and improve patient outcomes.
More about Regen Biopharma Inc 's Market Share
|
Celyad Oncology Sa
Share Performance
-6.00%
This Year
|
Celyad Oncology Sa
Profile
Celyad Oncology SA operates as a clinical-stage biopharmaceutical company. They focus on the development of CAR-T cell-based immunotherapies for the treatment of cancer, leveraging their proprietary technology platform.
More about Celyad Oncology Sa's Market Share
|
Histogen Inc
Share Performance
-2.49%
This Quarter
|
Histogen Inc
Profile
Histogen Inc operates as a biopharmaceutical company that focuses on developing and commercializing regenerative medicine therapies. Their business model revolves around researching and developing innovative products that stimulate the body's natural regenerative processes to treat various medical conditions and diseases. They aim to bring these therapies to market through partnerships, licensing agreements, and direct sales, providing healthcare solutions through their regenerative medicine technologies.
More about Histogen Inc 's Market Share
|
Soligenix inc
Share Performance
-2.79%
Over The Past 5 Days
|
Soligenix inc
Profile
Soligenix Inc. is a biopharmaceutical company that focuses on developing and commercializing products to treat rare diseases. Their business model revolves around leveraging their expertise in developing innovative therapies and securing partnerships and collaborations with academic institutions, government agencies, and other companies to accelerate the development process. Soligenix also strategically seeks funding through grants and licensing deals to support their pipeline and growth initiatives.
More about Soligenix inc 's Market Share
|
International Stem Cell Corporation
Share Performance
-10.66%
30 Days
|
International Stem Cell Corporation
Profile
International Stem Cell Corporation is a biotechnology company that focuses on developing and commercializing stem cell-based therapeutic products. They utilize their unique technology to derive unlimited amounts of pluripotent stem cells, enabling them to create therapeutics for various medical conditions.
More about International Stem Cell Corporation's Market Share
|
Ampio Pharmaceuticals inc
Share Performance
0.00%
30 Days
|
Ampio Pharmaceuticals inc
Profile
Ampio Pharmaceuticals Inc is a biopharmaceutical company primarily focused on the development of therapies for debilitating diseases. Their business model revolves around identifying unmet medical needs and developing innovative drug candidates to address these needs. They aim to create value through successful clinical development and commercialization of their products, ultimately benefiting patients and generating revenue for the company.
More about Ampio Pharmaceuticals inc 's Market Share
|
Ainos Inc
Share Performance
-62.79%
One Year
|
Ainos Inc
Profile
Ainos Inc is a software development company that generates revenue by providing custom software solutions and consulting services to businesses. They offer tailored software solutions to address specific customer needs and provide consulting expertise to guide companies in optimizing their software development processes.
More about Ainos Inc 's Market Share
|
Tff Pharmaceuticals Inc
Share Performance
-77.57%
Over The Past 5 Days
|
Tff Pharmaceuticals Inc
Profile
TFF Pharmaceuticals Inc's business model revolves around developing and commercializing novel drug therapies using its Thin Film Freezing (TFF) technology, which enhances the solubility and stability of drugs for improved delivery and patient outcomes. They collaborate with pharmaceutical and biotechnology companies to enhance their existing drug compounds and expand their market potential through licensing and partnership agreements.
More about Tff Pharmaceuticals Inc's Market Share
|
Sigilon Therapeutics Inc
Share Performance
+2,898.00%
One Year
|
Sigilon Therapeutics Inc
Profile
Sigilon Therapeutics Inc is a biotechnology company that focuses on developing novel therapies using advanced cell engineering and implantable devices to treat chronic diseases.
More about Sigilon Therapeutics Inc 's Market Share
|
Conduit Pharmaceuticals Inc
Share Performance
-99.68%
One Year
|
Conduit Pharmaceuticals Inc
Profile
Conduit Pharmaceuticals Inc's business model revolves around the development and commercialization of pharmaceutical products.
More about Conduit Pharmaceuticals Inc 's Market Share
|
Moleculin Biotech Inc
Share Performance
-85.56%
One Year
|
Moleculin Biotech Inc
Profile
Moleculin Biotech Inc is a biopharmaceutical company that develops innovative cancer therapies by targeting key enzymes and signaling pathways involved in the progression of tumors. Their business model revolves around conducting preclinical and clinical trials to advance their drug candidates, with a focus on maximizing therapeutic impact and commercial potential.
More about Moleculin Biotech Inc 's Market Share
|
Scisparc Ltd
Share Performance
+27.21%
This Quarter
|
Scisparc Ltd
Profile
Scisparc Ltd operates through a specific business model that focuses on providing innovative technological solutions in a particular industry or market.
More about Scisparc Ltd 's Market Share
|
Ardelyx Inc
Share Performance
-32.50%
One Year
|
Ardelyx Inc
Profile
Ardelyx Inc is a biopharmaceutical company that focuses on the development of novel, minimally-absorbed small molecules to treat gastrointestinal diseases. Their business model revolves around identifying specific needs within the gastrointestinal field and leveraging their research and development capabilities to create innovative therapeutic solutions. By partnering with other pharmaceutical companies and pursuing strategic collaborations, Ardelyx aims to bring its products to market and ultimately improve patient outcomes in the gastrointestinal space.
More about Ardelyx Inc 's Market Share
|
Praxis Precision Medicines Inc
Share Performance
-3.14%
Over The Past 5 Days
|
Praxis Precision Medicines Inc
Profile
Praxis Precision Medicines Inc's business model revolves around developing precision medicines for the treatment of various central nervous system (CNS) disorders.
More about Praxis Precision Medicines Inc 's Market Share
|
Cerevel Therapeutics Holdings Inc
Share Performance
+1.26%
Over The Past 5 Days
|
Cerevel Therapeutics Holdings Inc
Profile
Cerevel Therapeutics Holdings Inc operates as a biopharmaceutical company that focuses on developing and commercializing therapies for central nervous system disorders. Their business model revolves around innovative research and development to discover new treatments, strategic partnerships for financing and distribution, and ultimately bringing these therapies to market to improve the lives of patients with neurological conditions. They aim to address unmet medical needs in the field of neurology through their targeted drug development approach.
More about Cerevel Therapeutics Holdings Inc 's Market Share
|
Sources: Quoin Pharmaceuticals Ltd and all companies mentioned above in this report
|
